Human LILRB2/CD85d/ILT4 Affinity Purified Polyclonal Ab (25 UG)【科瑞奥博】

产品中心

当前位置：首页>产品中心

Human LILRB2/CD85d/ILT4 Affinity Purified Polyclonal Ab (25 UG)

货号： AF2078-SP 基本售价： 1378.1 元规格： -

产品信息

概述
货号	AF2078-SP
别名	CD85 antigen-like family member D; CD85d antigen; CD85d; Ig-like transcript 4; ILT4; ILT-4; ILT4CD85d; Immunoglobulin-like transcript 4; Leukocyte immunoglobulin-like receptor 2; leukocyte immunoglobulin-like receptor subfamily B member 2 soluble isoform; leukocyte immunoglobulin-like receptor subfamily B member 2; leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains); LIR2; LIR2CD85D; LIR-2subfamily A (with TM domain), member 6; member 2; MIR10; MIR10LILRA6; Monocyte/macrophage immunoglobulin-like receptor 10
全称	Leukocyte Immunoglobulin-like Receptor, Subfamily B (with TM and ITIM Domains), Member 5
反应种属	Human
应用	Western Blot(0.1 µg/mL) Flow Cytometry(2.5 µg/10⁶cells)
目标/特异性	Detects human LILRB2/CD85d/ILT4 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 35% cross-reactivity with recombinant human (rh) ILT2 is observed and 5% cross-reactivity with rhILT5 is observed.
使用方法	Western Blot: 0.1 µg/mL Flow Cytometry: 2.5 µg/10⁶cells Neutralization: Measured by its ability to neutralize LILRB2/CD85d/ILT4-mediated adhesion of the HSB2 human peripheral blood acute lymphoblastic leukemia cell line. Cosman, D. et al. (1997) Immunity 7:273. The Neutralization Dose (ND₅₀) is typically 0.3-1.0 µg/mL in the presence of 35 µg/mL Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera.
来源	Polyclonal Goat IgG
产品组分

性能
供应商	R&D Systems
Entrez Gene IDs	10288 (Human)
应用文献
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. IL-10 inhibits endothelium-dependent T cell costimulation by up-regulation of ILT3/4 in human vascular endothelial cells. Authors: Gleissner CA, Zastrow A, Klingenberg R, Kluger MS, Konstandin M, Celik S, Haemmerling S, Shankar V, Giese T, Katus HA, Dengler TJ Eur. J. Immunol., 2007;37(1):177-92. Species: Human Sample Type: Whole Cells Application: Neut
纯化方式	Antigen Affinity-purified
免疫原	Mouse myeloma cell line NS0-derived recombinant human LILRB2/CD85d/ILT4 Gly24-His458 Accession # AAC51882
内毒素水平	<0.10 EU per 1 μg of the antibody by the LAL method.
生物活性	Human
标记	Unconjugated
溶解方法	Reconstitute at 0.2 mg/mL in sterile PBS.
背景	The immunoglobulin-like transcript (ILT) comprise a family of activating and inhibitory type immunoreceptors whose genes are located in the same locus that encodes killer cell Ig-like receptors (KIR) (1‑3). ILT4, also known as LIR-2 and LILRB2, is a type I transmembrane protein expressed primarily on monocytes and dendritic cells (DC) (4). Human ILT4 is produced as a 598 amino acid (aa) precursor including a 21 aa signal sequence, a 440 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 116 aa cytoplasmic domain. The ECD contains four Ig-like domains, and the cytoplasmic domain contains three immunoreceptor tyrosine-based inhibitory motifs (ITIM) (5). The ECD of human ILT4 shares 76% aa identity with chimpanzee ILT4 and 74%, 81%, 33%, 52%, 77%, 61%, and 64% aa identity with human ILT1, 2, 3, 5, 6, 7, and 8, respectively. ILT4 binds to classical MHC I proteins as well as the non-classical HLA-G1 and HLA-F molecules (5‑9). It competes with CD8 alpha for MHC I binding but does not compete with KIR2DL1 (7). Ligation of ILT4 induces Tyr phosphorylation within its cytoplasmic ITIMs, a requirement for association with SHP-1 (4, 6). Activation of ILT4 inhibits signaling through Fc gamma RI (4) and Fc epsilon RI (6) and causes DC to become tolerogenic by down-regulation of co-stimulatory molecules (10, 11). ILT4 mediates tolerogenic DC-induced CD4⁺ T cell energy in vitroandin vivo (10‑12).
运输条件	Blue Ice
存放说明	4℃
参考文献	Suciu-Foca, N. et al. (2005) Int. Immunopharmacol. 5:7. Hofmeister, V. and E.H. Weiss (2003) Semin. Canc. Biol. 13:317. Hunt, J.S. et al. (2005) FASEB J. 19:681. Finger, N.A. et al. (1998) Eur. J. Immunol. 28:3423. Borges, L. et al. (1997) J. Immunol. 159:5192. Colonna, M. et al. (1998) J. Immunol. 160:3096. Shiroishi, M. et al. (2003) Proc. Natl. Acad. Sci. 100:8856. Lepin, E.J.M. et al. (2000) Eur. J. Immunol. 30:3552. Allen, R.L. et al. (2001) J. Immunol. 167:5543. Chang, C.C. et al. (2002) Nat. Immunol. 3:237. Ristich, V. et al. (2005) Eur. J. Immunol. 35:1133. Manavalan, J.S. et al. (2003) Transpl. Immunol. 11:245.

参考图片

Cell Adhesion Mediated by LILRB2/CD85d/ILT4 and Neutralization by Human LILRB2/CD85d/ILT4 Antibody. Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera (Catalog # 2078-T4), immobilized onto a microplate, supports the adhesion of the HSB2 human peripheral blood acute lymphoblastic leukemia cell line in a dose-dependent manner (orange line). Adhesion elicited by Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera (35 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human LILRB2/CD85d/ILT4 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2078). The ND₅₀ is typically 0.3-1.0 µg/mL.